Bicara Therapeutics Inc. Common Stock
BCAX | NASDAQ
$22.74
+$0.73 (+3.32%)
Sep 22, 2026, 11:22 AM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 |
|---|---|---|---|---|
Net Income | -137.95M | -68M | -51.99M | -37.85M |
Depreciation & Amortization | 406K | 56K | 19K | 10K |
Stock-Based Compensation | 15.01M | 7.4M | 1.9M | 810K |
Other Working Capital | 14.81M | -16.77M | -9.62M | 4.95M |
Other Non-Cash Items | 895K | -77K | 14.06M | 810K |
Deferred Income Tax | n/a | n/a | n/a | n/a |
Change in Working Capital | 14.81M | -14.13M | -9.62M | 4.95M |
Operating Cash Flow | -106.83M | -74.75M | -45.63M | -32.08M |
Capital Expenditures | -280K | -71K | -586K | -192K |
Cash Acquisitions | n/a | n/a | n/a | n/a |
Purchase of Investments | -318.17M | n/a | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a | n/a |
Other Investing Acitivies | n/a | 62K | n/a | n/a |
Investing Cash Flow | -318.45M | -9K | -586K | -192K |
Debt Repayment | n/a | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a | n/a |
Other Financial Acitivies | n/a | 1.6M | 149K | 160K |
Financial Cash Flow | 32.26M | 334.03M | 272.5M | 31.7M |
Net Cash Flow | -393.03M | 259.27M | 226.28M | -573K |
Free Cash Flow | -107.11M | -74.82M | -46.21M | -32.27M |
Adj. Free Cash Flow | -122.12M | -82.22M | -48.11M | -33.08M |
Maintenance CapEx | -280K | -56K | -19K | -10K |
Growth CapEx | n/a | -15K | -567K | -182K |
Owner Earnings | -107.11M | -74.81M | -45.65M | -32.09M |
Add to Watchlist
Select watchlists to add or remove BCAX